Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 25 versus ORETICYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 25 versus ORETICYL FORTE.
CAPOZIDE 50/25 vs ORETICYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One tablet (captopril 50 mg / hydrochlorothiazide 25 mg) orally once daily; may increase to two tablets daily if needed.
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
None Documented
None Documented
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: dosing interval typically 12-24 hours.
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours.
Captopril: 95% renal (primarily unchanged). Hydrochlorothiazide: 95% renal (unchanged).
Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces.
Category C
Category C
ACE Inhibitor/Diuretic Combination
Diuretic Combination